Date: 2017-03-01
Type of information: Opening of new premises
Compound: U.S. headquarters
Company: Adaptimmune (UK)
Therapeutic area: Cancer - Oncology
Type agreement: opening of new premises
Action mechanism:
Disease:
Details:
- • On March 1, 2017, Adaptimmune Therapeutics has hosted a ribbon cutting ceremony at the Navy Yard in Philadelphia to celebrate the opening of its newly constructed U.S. headquarters and base for clinical and manufacturing operations. Developed by Liberty Property Trust and Synterra Partners, and under advisement of CBRE’s Life Science Advisory and Project Management Group, this 47,400 square foot facility, located at 351 Rouse Boulevard will include a state-of-the-art cGMP manufacturing facility designed to support Adaptimmune's clinical development objectives and the initial commercialization of novel engineered immunotherapies for cancer. Adaptimmune’s Navy Yard facility currently houses 91 employees; this number is expected to grow to 120 by the end of 2017.
- Announced in October 2015, this project was coordinated by the Governor’s Action Team and received a funding proposal from the Department of Community and Economic development that included a Pennsylvania First Program grant for $150,000.
- Adaptimmune launched its US operations in Philadelphia in 2011. The Company expanded its programs while operating out of the University City Science Center, Philadelphia.
Financial terms:
Latest news:
Is general: Yes
